Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - amoksicilinas/klavulano rūgštis - plėvele dengtos tabletės - 500 mg/125 mg - amoxicillin and beta-lactamase inhibitor

Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - lansoprazolas - skrandyje neirios kietosios kapsulės - 30 mg - lansoprazole

Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - meropenemas - milteliai injekciniam ar infuziniam tirpalui - 500 mg; 1 g - meropenem

Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia ingen pharma - amoksicilinas/klavulano rūgštis - plėvele dengtos tabletės - 875 mg/125 mg - amoxicillin and beta-lactamase inhibitor

Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - amoksicilinas/klavulano rūgštis - plėvele dengtos tabletės - 875 mg/125 mg - amoxicillin and beta-lactamase inhibitor

Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - midazolamas - injekcinis ar infuzinis tirpalas - 5 mg/ml - midazolam

Litwania - Kilithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - ketorolako trometamolis - injekcinis tirpalas - 30 mg/ml - ketorolac

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenemo natrio druska - bakterinė infekcija - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 ir 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcio homeostazė - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.